[Xantinol-nicotinate in primary type-V hyperlipoproteinaemia (author's transl)].
The effect of xantinol-nicotinate (50 mg/kg body-weight) on serum lipids and lipoproteins was tested in 16 out-patients with primary type V hyperlipoproteinaemia. The lipids and lipoproteins were measured before treatment, during a three-week period of drug administration and ten days after it had been stopped. There were no side effects such as flushing or gastritis, and no notable reduction of weight. Each serum-lipid fraction (triglycerides, nonesterified fatty acids, phospholipids, ester-cholesterol and free cholesterol) decreased significantly, regaining the initial values ten days after the drug had been stopped. While chylomicrons and very low-density lipoproteins (VLDL) decreased, there was a significant increase in low-density lipoproteins (LDL). High-density lipoproteins were not significantly changed. The decrease in chylomicrons and the significant decrease in VLDL with xantinol-nicotinate was opposite to that seen with dietary treatment. In none of the patients did LDL increase to abnormally high levels.
D000328:Adult; D000368:Aged; D001835:Body Weight; D002784:Cholesterol / Q000097:blood; D002914:Chylomicrons / Q000097:blood; D005230:Fatty Acids, Nonesterified / Q000097:blood; D005260:Female; D006801:Humans; D006949:Hyperlipidemias / Q000188:drug therapy*; D008055:Lipids / Q000097:blood; D008074:Lipoproteins / Q000097:blood; D008075:Lipoproteins, HDL / Q000097:blood; D008079:Lipoproteins, VLDL / Q000097:blood; D008297:Male; D008875:Middle Aged; D010743:Phospholipids / Q000097:blood; D013806:Theophylline / Q000031:analogs & derivatives*; D013997:Time Factors; D014280:Triglycerides / Q000097:blood; D014971:Xanthinol Niacinate / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*
D002914:Chylomicrons; D005230:Fatty Acids, Nonesterified; D008055:Lipids; D008074:Lipoproteins; D008075:Lipoproteins, HDL; D008079:Lipoproteins, VLDL; D010743:Phospholipids; D014280:Triglycerides; D014971:Xanthinol Niacinate; D002784:Cholesterol; D013806:Theophylline
Xantinol-nicotinat bei primärer Typ-V-Hyperlipoproteinämie. Wirkung auf Lipide und Serumlipoproteine